Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model

The newer rifamycin, rifalazil (RLZ) (previously known as KRM-1648), has been shown in prior experiments to be a highly potent drug against Mycobacterium tuberculosis. In this report, we studied the efficacy of RLZ in combination with pyrazinamide (PZA) and ethambutol (EMB) in a long-term in vivo ex...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Lenaerts, Anne M., Chase, Sharon E., Cynamon, Michael H.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2000
Assuntos:	Experimental Therapeutics
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101623/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11036043/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.11.3167-3168.2000
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!